Literature DB >> 11086857

Developments in preclinical AIDS vaccine efficacy models.

W M Bogers1, C Cheng-Mayer, R C Montelaro.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 11086857

Source DB:  PubMed          Journal:  AIDS        ISSN： 0269-9370            Impact factor:   4.177


× No keyword cloud information.
  15 in total

1.  Increased mucosal transmission but not enhanced pathogenicity of the CCR5-tropic, simian AIDS-inducing simian/human immunodeficiency virus SHIV(SF162P3) maps to envelope gp120.

Authors:  Mayla Hsu; Janet M Harouse; Agegnehu Gettie; Clarisa Buckner; James Blanchard; Cecilia Cheng-Mayer
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

2.  Addition of a single gp120 glycan confers increased binding to dendritic cell-specific ICAM-3-grabbing nonintegrin and neutralization escape to human immunodeficiency virus type 1.

Authors:  James Lue; Mayla Hsu; David Yang; Preston Marx; Zhiwei Chen; Cecilia Cheng-Mayer
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

3.  Induction of potent local cellular immunity with low dose X4 SHIV(SF33A) vaginal exposure.

Authors:  Silvana Tasca; Lily Tsai; Nataliya Trunova; Agegnehu Gettie; Mohammed Saifuddin; Rudolf Bohm; Lisa Chakrabarti; Cecilia Cheng-Mayer
Journal:  Virology       Date:  2007-06-15       Impact factor: 3.616

4.  Envelope variation as a primary determinant of lentiviral vaccine efficacy.

Authors:  Jodi K Craigo; Baoshan Zhang; Shannon Barnes; Tara L Tagmyer; Sheila J Cook; Charles J Issel; Ronald C Montelaro
Journal:  Proc Natl Acad Sci U S A       Date:  2007-09-10       Impact factor: 11.205

5.  Dynamic evolution of antibody populations in a rhesus macaque infected with attenuated simian immunodeficiency virus identified by surface plasmon resonance.

Authors:  J D Steckbeck; H J Grieser; T Sturgeon; R Taber; A Chow; J Bruno; M Murphy-Corb; R C Montelaro; K S Cole
Journal:  J Med Primatol       Date:  2006-08       Impact factor: 0.667

6.  The comparison of genetic variation in the envelope protein between various immunodeficiency viruses and equine infectious anemia virus.

Authors:  Qing Yuan; Chang Liu; Zhipin Liang; Xueqing Chen; Danhong Diao; Xiaohong Kong
Journal:  Virol Sin       Date:  2012-07-28       Impact factor: 4.327

7.  V3 loop-determined coreceptor preference dictates the dynamics of CD4+-T-cell loss in simian-human immunodeficiency virus-infected macaques.

Authors:  Siu-hong Ho; Lili Shek; Agegnehu Gettie; James Blanchard; Cecilia Cheng-Mayer
Journal:  J Virol       Date:  2005-10       Impact factor: 5.103

8.  Discerning an effective balance between equine infectious anemia virus attenuation and vaccine efficacy.

Authors:  Jodi K Craigo; Feng Li; Jonathan D Steckbeck; Shannon Durkin; Laryssa Howe; Sheila J Cook; Charles Issel; Ronald C Montelaro
Journal:  J Virol       Date:  2005-03       Impact factor: 5.103

9.  AIDS vaccination studies using an ex vivo feline immunodeficiency virus model: failure to protect and possible enhancement of challenge infection by four cell-based vaccines prepared with autologous lymphoblasts.

Authors:  Simone Giannecchini; Patrizia Isola; Olimpia Sichi; Donatella Matteucci; Mauro Pistello; Lucia Zaccaro; Daniela Del Mauro; Mauro Bendinelli
Journal:  J Virol       Date:  2002-07       Impact factor: 5.103

10.  Envelope determinants of equine infectious anemia virus vaccine protection and the effects of sequence variation on immune recognition.

Authors:  Tara L Tagmyer; Jodi K Craigo; Sheila J Cook; Deborah L Even; Charles J Issel; Ronald C Montelaro
Journal:  J Virol       Date:  2008-01-30       Impact factor: 5.103
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.